Overview

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

Status:
Withdrawn
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the effect of chemotherapy on decreasing the size of unresectable pancreas cancer thereby allowing it to be surgically removed. In addition, this study may provide information on how tumors behave when exposed to certain types of chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cincinnati
Collaborator:
Sanofi
Treatments:
Erlotinib Hydrochloride
Gemcitabine
Oxaliplatin